5 IU/ml and can be concentrated by ultracentrifugation to titers of 10 7 IU/ml. HIV(ALSV-A) also infects embryonic fibroblasts derived from transgenic mice in which TVA expression is driven by the ␤-actin promoter. In addition, this lentivirus pseudotype efficiently infects these fibroblasts after cell cycle arrest, when they are resistant to infection by ALSV vectors. This system may be useful for introducing genes into somatic cells in adult TVA transgenic animals and allows evaluation of the effects of altered gene expression in differentiated cell types in vivo.
Avian leukosis-sarcoma viruses (ALSV) have the ability to infect avian cells efficiently and replicate to high titer. Mammalian cells, however, are resistant to infection by these avian retroviruses and produce undetectable levels of infectious virus when rare infections occur (32) . In 1993, Bates et al. cloned the gene that encodes the receptor for subgroup A ALSV (ALSV-A), termed TVA, and demonstrated that exogenous production of TVA on the surface of mammalian cells was both necessary and sufficient for the efficient infection of mammalian cells by ALSV-A (1, 34) . Since susceptibility to infection is conferred by TVA, tissue-and cell type-specific infection in vivo can be achieved by expressing TVA from cell type-or tissue-specific promoters in transgenic animals. Federspiel et al. first demonstrated the utility of this system through specific infection of myocytes in which expression of TVA was directed by the ␣-actin promoter (6) . Subsequent studies have demonstrated that this phenomenon is not restricted to a single cell type (8, 13, 21) .
We are utilizing the TVA system to generate mouse tumor models for several types of human malignancy (8) . In the mouse models generated to date, the target organs are readily accessible at birth, allowing the delivery of replication-competent ALSV vectors at a time when the target cells are still actively proliferating. However, in other organ systems, such as the pancreas, the target cells are not accessible at birth and proliferate very slowly in the adult animal (5) . Like other classical retroviruses, ALSV vectors require cells to be actively dividing for the establishment of a provirus to occur (16, 19, 28) . Therefore, for infection of nondividing cells in vivo, a retroviral vector that can generate a provirus in the absence of cell division is required.
Lentiviruses can integrate viral DNA into the genomes of nondividing cells (16, 19, 28) . Naldini et al. have previously described the generation of a replication-deficient human immunodeficiency virus type 1 (HIV-1)-based vector pseudotyped with the vesicular stomatitis virus (VSV) envelope glycoprotein (VSVG) (22, 23) . This vector can be generated at titers of 10 6 infectious units (IU)/ml and can infect many species and cell types. In addition, this vector was also shown to be more effective than a VSVG pseudotyped murine leukemia virus (MLV) vector at infecting several cell lineages in adult animals in vivo (15, 22, 23) . Subsequently, other HIV-based pseudotypes have been described, as well as vectors based on other lentiviruses (25, 26, 27, 30) .
To expand the utility of TVA technology, we sought to develop a replication-deficient, HIV-1-based lentiviral vector, pseudotyped with the envelope glycoprotein for ALSV subgroup A, named HIV(ALSV-A). We show here that this lentiviral vector can be produced at titers greater than 5 ϫ 10 4 IU/ml and that it is stable during ultracentrifugation and can thus be concentrated to titers of 10 7 IU/ml. This vector retains the specificity of ALSV-based vectors, infecting only those mammalian cells engineered to express TVA. Further, this vector infects primary cells from multiple mouse tissues in culture and infects cell cycle-arrested mouse embryo fibroblasts (MEFs) that are resistant to infection by ALSV vectors. The development of this pseudotyped lentivirus vector will To expand the use of TVA-mediated gene delivery, we sought to develop a lentiviral vector whose entry is dependent on the presence of TVA on the surface of target cells. To generate pseudotyped HIV-based vectors, three plasmids-pCS-CG, which encodes GFP driven by the CMV promoter; pCMV⌬R 8.2, which encodes the HIV structural and accessory proteins; and either pCB6WTA, encoding the ALSV-A envelope glycoprotein, or pMD.G, which encodes the VSVG envelope glycoprotein-were cotransfected into 293T cells, and the viral supernatant was harvested 60 to 65 h after transfection. The collected supernatants were placed on 293 cells engineered to express TVA (293-TVA cells) and parental 293 cells. More than 95% of 293-TVA cells were infected by the EnvA pseudotyped viral particles [HIV(ALSV-A)], whereas the parental 293 cells were not infected (Fig. 1) . However, both cell lines were equally susceptible to infection by VSVG pseudotyped HIV particles [HIV(VSVG)] (Fig. 1B) . These data demonstrate that the ALSV-A envelope can pseudotype HIV-1-based vectors and that these pseudotyped vectors require the presence of TVA on the surface of target cells for infection. 293-TVA cells infected with the HIV(ALSV-A) vector maintained expression of the GFP cassette for greater than 10 months (data not shown).
RESULTS

Generation
Having demonstrated that EnvA can pseudotype an HIV vector, we next sought to determine whether HIV accessory proteins, such as vpr, vpu, and nef, affect the infectious titer of the pseudotype. Vector particles were generated with plasmid pCMV⌬R 8.2, which encodes all of the accessory proteins, or pCMV⌬R 8.91, in which all accessory protein genes are deleted. Similar infectious titers were obtained with both constructs, suggesting that the HIV accessory proteins do not strongly influence the ability of the generated vector to infect 293-TVA cells ( Table 1) .
The HIV-1 central polypurine tract and altered ALSV-A envelopes increase the vector titer. The work of Naldini et al., and subsequently of several other groups, demonstrated that the HIV(VSVG) vector can be generated at titers of ca. 10 6 to 10 7 particles per ml, whereas the titer of the HIV(ALSV-A) vector was consistently less than 10 4 IU/ml (15, 22, 36) . Since the only difference between the two pseudotypes is the envelope glycoprotein and since the cytoplasmic tail of the transmembrane segment of the envelope is the only region that contacts the HIV core, we hypothesized that the cytoplasmic tail of the ALSV-A envelope might be inhibiting particle formation. We therefore generated a plasmid encoding EnvA truncated at residue 513, just beyond the membrane spanning region (pCB6 WTA⌬513), and a plasmid encoding a chimera in which the cytoplasmic tail of EnvA was replaced with that of VSVG (pCB6WTA VCT). These modified ALSV-A envelope proteins are shown in schematic form in Fig. 2A . Substitution of full-length EnvA with either of these proteins resulted in a fivefold increase in infectious titer to 1.7 ϫ 10 4 IU/ml as determined by serial dilution (Fig. 2C) .
Recent work has demonstrated the presence of a short purine-rich sequence (cPPT) within the HIV-1 pol gene that acts to generate a "plus-strand" flap in the double-stranded viral DNA prior to integration. This flap was shown to be important for efficient nuclear import of viral DNA (35) . Furthermore, other recent work has demonstrated that insertion of this sequence into the expression plasmid increases the infectious titer of HIV(VSVG) fivefold (9) . We therefore modified pCS-CG to include the cPPT sequence and measured its effect on the infectious titer of HIV(ALSV-A) (Fig. 2B) . Consistent with the published work, we observed a fivefold increase in the infectious titer from 0.34 ϫ 10 4 to 1.6 ϫ 10 4 IU/ml after insertion of the cPPT sequence (Fig. 2C) .
When both the cPPT sequence and the altered envelopes were included in the vector particles, a synergistic effect was observed, with the titers increased by ca. 20-fold to 6.5 ϫ 10 4 IU/ml (Fig. 2C) . In subsequent experiments, we have achieved virus preparations with titers of 10 5 IU/ml that can be concentrated by ultracentrifugation to titers of 10 7 IU/ml after a 100-fold reduction in volume. In our experiments we routinely recover 75 to 100% of the infectious particles.
When we determined the physical titers of the ALSV-A pseudotypes by using an HIV-1 p24 ELISA, we measured 5.62 Ϯ 0.92 ng of p24/ml for the vector generated with wildtype EnvA and minus cPPT, where 1 ng of p24 is equivalent to ca. 1,000 to 5,000 viral particles (Fig. 2C) (36) . This corresponds to a physical titer Ͼ15 times higher than the infectious titer determined by serial dilution on 293-TVA cells, suggesting that the majority of p24 was present in noninfectious viral particles. In contrast, we find that the titers determined by serial dilution and p24 ELISA for the HIV(VSVG) vector were similar (data not shown), implying a high specific infectious activity. When we measured the levels of p24 in vector particles with the cPPT sequence and modified envelope proteins, we observed that these changes did not increase the physical titer, although the infectious titers of these vectors were 5-to 20-fold higher (Fig. 2C) . Therefore, the insertion of the cPPT sequence into the expression cassette and the removal of the cytoplasmic tail of EnvA act to increase the specific infectivity of the HIV(ALSV-A) vector (Fig. 2C) .
Host range of HIV(ALSV-A). Our main purpose in developing the HIV(ALSV-A) pseudotype was to generate a vector for in vivo gene delivery to stationary cells in TVA transgenic mice. We therefore tested the ability of HIV(ALSV-A) to infect primary mouse cells in culture, as well as cells from two additional nonprimate species, the rat and the chicken, to judge the host range of the pseudotype. The HIV(ALSV-A) vector was 5 to 10 times less efficient at infecting rodent cells than human 293-TVA cells and was a further 10-fold less efficient at infecting chicken cells (Table 2 ). In comparison, the ALSV-A vector, RCAS-GFP, infects MEFs ca. 30% as efficiently as 293-TVA cells (Table 2 ). In contrast to the HIV-(ALSV-A) vector, the HIV-GFP(VSVG) vector was able to infect human, rat, and chicken cells with equal efficiency, although it was only half as efficient at infecting MEFs (Table 2) . It is possible that the reduced infection of MEFs observed with all vectors reflects a difference between primary cells and immortalized cell lines.
Infection of nondividing cells by HIV(ALSV-A).
The advantage of lentiviral vectors over classical retroviral vectors is their ability to infect nondividing cells (16) . We therefore examined the ability of HIV(ALSV-A) to infect cells arrested during the cell cycle. MEFs from transgenic mice carrying the ␤-actin TVA transgene were arrested by either gamma irradiation or colcemid treatment. Cells were infected 30 h after the induction of arrest, and cell cycle arrest was verified through propidum iodide staining and flow cytometric analysis. The HIV-(ALSV-A) pseudotype infected the arrested cells as efficiently as it did exponentially growing cells, whereas RCAS-GFP was (Table 3) . Next, we determined the ability of HIV(ALSV-A) to infect cells that had exited the cell cycle into G 0 . We allowed MEFs to exit the cell cycle into G 0 by growing them to confluence and maintaining the cultures in 0.1% serum for 3 days after confluence. Cells were then infected with either RCAS-GFP or HIV-GFP(ALSV-A) vectors. Only HIV(ALSV-A) was able to infect the G 0 cells (data not shown). Thus, like other HIVbased vectors, the ALSV pseudotype retains the ability to infect cells arrested during the cell cycle, as well as those which have exited the cell cycle into G 0 .
DISCUSSION
ALSV cannot efficiently infect mammalian cells unless these cells are engineered to express the ALSV receptor on their surface (32) . The TVA system provides a mechanism to deliver genes in a tissue-specific manner in vivo (6) . The gene delivery vectors currently used with this system are all ALSV-based vectors and, as such, have an absolute requirement for cell division for the establishment of infection (16, 19, 28) . Indeed, in their initial test of the TVA system in vivo, utilizing ␣-actin TVA transgenic mice, Federspiel et al. found that the ability of the ALSV vector to infect cells in the myocyte lineage dramat- ically decreased within a few days after birth (6) . The requirement for cell division thus limits the systems to which the TVA technology can be applied.
We have described here the production of a replicationdeficient, ALSV-A pseudotyped HIV-1 vector, HIV(ALSV-A). This virus, like the HIV(VSVG) pseudotype, is not produced in the target cells and therefore does not spread to infect neighboring cells. We have demonstrated that infection by HIV(ALSV-A) requires the presence of TVA on the surface of mammalian cells. Thus, using TVA transgenic mice, HIV-(ALSV-A) infection can be cell type or tissue restricted in vivo.
HIV(ALSV-A) can be generated at infectious titers approaching 10 5 IU/ml and is stable during ultracentrifugation and can therefore be concentrated to titers of 10 7 IU/ml. This titer should be adequate for many in vivo and in vitro applications, particularly in circumstances in which ALSV vectors are ineffective because cells are in a resting state. Our data suggest, at least for 293 cells, that the absence of the HIV accessory proteins does not affect the ability of the pseudotype to infect these cells. However, an extensive study of multiple cell types was not conducted, and it is possible that there are cell types in which specific HIV-1 accessory proteins may affect infection efficiency. Indeed, there are conflicting reports in the literature concerning the requirement of the accessory factors in certain cell types (2, 15, 24) .
The ability of EnvA to pseudotype the HIV vector is poor relative to the VSVG envelope glycoprotein, as demonstrated by its relatively low physical and infectious titers. While several heterologous envelopes, such as those of MLV, can pseudotype HIV-based vectors, others, such as that of gibbon ape leukemia virus (GALV), have failed to effectively pseudotype HIV-1-based vectors (27, 30 ; N. Chinnasamy and R. A. Morgan, unpublished data). We were able to increase the infectious titer of the ALSV pseudotype fivefold by using altered ALSV-A envelope proteins without increasing vector particle formation, suggesting that there are conformational constraints present in wild-type EnvA pseudotyped vectors that prevent proper interaction with receptors. Consistent with this idea, Stitz et al. recently reported that while wild-type GALV envelope cannot form an infectious pseudotype, chimeric GALV or MLV envelopes are capable of forming an infectious HIV-based pseudotype (30) .
The HIV(ALSV-A) vector demonstrated the ability to infect cells of human and rodent origin, as did the ALSV-A vector RCAS-GFP. Although the titers for RCAS-GFP and HIV-GFP(ALSV-A) were determined by using different methods, an approximate comparison of the efficiencies of infection can be made. We found that, while both vectors infect 293-TVA cells with similar efficiency, RCAS-GFP is three times more efficient than HIV-GFP(ALSV-A) at infecting dividing MEFs. However, we found that this difference is not apparent for all cell types. Astrocytes from transgenic mice in which TVA expression is driven by the nestin promoter are infected at similar efficiency by both vectors. The HIV(ALSV-A) vector infects chicken cells poorly relative to its ability to infect cells of human and rodent origin. In contrast, we find that an HIV (VSVG) pseudotype is able to infect the chicken cell line DF-1 as efficiently as it does cells of human and rodent origin. One possible reason for the discrepancy between the two pseudotypes may lie in the different entry mechanisms of VSV and ALSV. ALSV utilizes glycoprotein receptors on the membrane surface, whereas VSV has been shown to fuse directly with membrane phospholipids (1, 17, 31, 33, 34) . However, we have not formally investigated whether there are differences in other steps during the establishment of infection. Another possible explanation for the difference may be that endogenous TVA expression on DF-1 cells is very low in comparison to that generated in the 293 cell line and MEFs by the potent CMV and ␤-actin promoters.
We have further demonstrated in this work that HIV-(ALSV-A) can readily infect primary murine cells that are arrested in the cell cycle or have exited the cell cycle. MEFs treated with either colcemid or gamma irradiation to induce cell cycle arrest were far less susceptible to infection by ALSV vectors but were equally susceptible to infection by HIV (ALSV-A) relative to logarithmically growing cells. Thus, the HIV(ALSV-A) pseudotype has the characteristic ability of other lentiviral vectors to infect nondividing cells.
Currently, the TVA system and ALSV vectors are used predominantly to generate mouse tumor models. Recently, however, Doetsch et al. and Murphy and Leavitt have used this system to monitor precursors of the glial and megakaryocyte cell lineages, respectively (4, 21) . Previous studies have demonstrated effective gene delivery to liver, brain, and lung epithelia and to cells of the hematopoeitic lineage by HIV (VSVG), illustrating that lentivirus vectors can deliver genes efficiently to nondividing cells in vivo (3, 11, 14, 15, 18, 22, 23) . These studies indicate that the HIV(ALSV-A) pseudotype should also provide an effective means of gene delivery to stationary cells in vivo. Thus, the development of the HIV (ALSV-A) pseudotype provides another valuable tool for groups interested in manipulating nondividing and terminally differentiated cells in vivo as a means to dissect molecular signaling and developmental pathways in these cells. 
